Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cameron Guild

Interventional Cardiology Jackson, MS Medical Doctor

NPI 1396771366 CMS profile 199380

501 Marshall St Ste 104, Jackson, MS 39202

Open in the dashboard

General payments

$4,447

156 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cameron Guild of Jackson, MS is reported in the CMS Open Payments database as having received $4,447 across 156 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $509 14
2024 General $587 15
2023 General $178 8
2022 General $638 28
2021 General $791 31
2020 General $581 21
2019 General $1,164 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cameron Guild
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Cameron Guild were reported at $509. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Cameron Guild Interventional Cardiology median Middle half National median
2019 $1,164 $1,097 $329–$3,048 $163
2020 $581 $473 $161–$1,480 $114
2021 $791 $677 $233–$1,827 $132
2022 $638 $978 $333–$2,724 $149
2023 $178 $1,136 $382–$2,986 $160
2024 $587 $1,181 $395–$3,326 $164
2025 $509 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $2,148 74 payments
  2. Novartis Pharmaceuticals Corporation $323 22 payments
  3. Abbott Laboratories $212 7 payments
  4. Boston Scientific Corporation $181 8 payments
  5. Inari Medical, Inc. $150 8 payments
  6. Novo Nordisk Inc $127 1 payment
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $125 3 payments
  8. HeartFlow, Inc. $121 1 payment
  9. Lantheus Medical Imaging, Inc. $120 1 payment
  10. AstraZeneca Pharmaceuticals LP $118 2 payments
  11. Other $823 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,447 156 payments
Products named General payments · program years 2019–2025
  1. Impella $2,148 74 payments
  2. FLOWTRIEVER CATHETER, S $284 15 payments
  3. ENTRESTO $242 17 payments
  4. JARDIANCE $125 3 payments
  5. FFRct $121 1 payment
  6. DEFINITY $120 1 payment
  7. KENGREAL $111 1 payment
  8. Tryvio $108 1 payment
  9. ELIQUIS $103 7 payments
  10. EKOSONIC $101 1 payment
  11. Other $1,039 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

4,231

Median for Interventional Cardiology: 2,236

Drug cost

$798,692

Median for Interventional Cardiology: $380,412

Branded share of claims

29.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 235 $259,459
Eliquis Apixaban Brand 254 $230,029
Jardiance Empagliflozin Brand 65 $88,704
Farxiga Dapagliflozin Propanediol Brand 66 $70,957
Xarelto Rivaroxaban Brand 50 $52,530
Repatha Sureclick Evolocumab Brand 46 $36,570
Praluent Pen Alirocumab Brand 22 $11,739
Metoprolol Succinate Generic 500 $6,131
Brilinta Ticagrelor Brand 12 $5,915
Trintellix Vortioxetine Hydrobromide Brand 12 $5,527

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$152,225

Medicare's payments for the services billed

Medicare patients

810

Average age 76

Services billed

2,354

455 women, 355 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 47%
Diabetes 41%
Heart failure 34%
Atrial fibrillation 34%
Chronic kidney disease 32%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $88
$88 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $31
$31 — —
ELIQUIS
  • PFIZER INC. $16
$16 254 —
XARELTO
  • Janssen Pharmaceuticals, Inc $15
$15 50 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record